Mattias Rudebeck

Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment

L. Ranganath, Anna M. Milan, Andrew T. Hughes et al. · Annals of the Rheumatic Diseases · 2014 · 157 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial

L. Ranganath, Eftychia Eirini Psarelli, Jean-Baptiste Arnoux et al. · The Lancet Diabetes & Endocrinology · 2020 · 123 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +3

Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study

Ute Spiekerkoetter, María L. Couce, Anibh M. Das et al. · The Lancet Diabetes & Endocrinology · 2021 · 36 citations

Life Sciences, Internal Medicine, Human Genetics +3

Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria

L. Ranganath, Anna M. Milan, Andrew T. Hughes et al. · Journal of Inherited Metabolic Disease · 2019 · 29 citations · Full text

Pharmacy, Nephrology, Physiology +13

Safety, Pharmacokinetics, and Efficacy of Palifermin in Children and Adolescents with Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic Hematopoietic Stem Cell Transplantation: A Pediatric Blood and Marrow Transplant Consortium Trial

Joan Morris, Mattias Rudebeck, Steven Neudorf et al. · Biology of Blood and Marrow Transplantation · 2016 · 19 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16